

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, Maryland 21244-1850



CENTER FOR BENEFICIARY CHOICES

October 4, 2006

Memorandum To: All Part D Sponsors

Subject: HPMS Q & A - Claims for MTMP services

From: Cynthia Tudor, Ph.D., Director, Medicare Drug Benefit Group

The following question and answer will be posted to the Frequently Asked Questions Database on the CMS website at <http://questions.cms.hhs.gov>.

Q:

When a Provider submits a claim to a Part D sponsor for a clinical service provided as part of a Medication Therapy Management Program (MTMP), should they submit the claim using the NCPDP 5.1 transaction standard or must they use the (ASC) X12N 837P Version 4010/4010A1 transaction standard?

A:

The American Standards Committee (ASC) X12N 837P Version 4010/4010A1.

We articulated in our January 28, 2005 Final Rule on the Medicare Prescription Drug Benefit that we viewed Medication Therapy Management (MTM) as a clinical service (70 FR 4194, 4231). Therefore, claims for MTM would be considered professional health care claims rather than retail pharmacy drug claims. Pursuant to the Health Insurance Portability and Accountability Act (HIPAA) of 1996, HHS adopted, in the August 17, 2000 Transactions and Code Sets Final Rule, the ASC X12N 837P Version 4010/4010A1 as the transaction standard for professional health care claims. Therefore, similar to physician clinical services, if MTM providers bill Part D sponsors electronically for MTM services, such billing claims must be transmitted using the ASC X12N 837P Version 4010/4010A1. Part D Sponsors are not precluded from using the NCPDP 5.1 system edits as a method to identify targeted beneficiaries, or provide applicable information at the point of service to pharmacists or other MTM providers responsible for providing the MTMP services, but the health care claim must be transmitted using the ASC X12N 837P.

For more information on HIPAA, Plans should refer to the following website for detailed information:

<http://www.cms.hhs.gov/HIPAAGenInfo/>

Please contact Greg Dill at (312) 353-1754 if you have any questions about this guidance.

